07:00 , Sep 8, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cutaneous T cell lymphoma (CTCL) MicroRNA-155 (miR-155); miR-203; miR-205 Studies in patient samples suggest differential expression of miRNAs could help diagnose CTCL. Microarray and PCR...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Clinical News

miRview squamous: Post-marketing study data

Researchers at Johns Hopkins University School of Medicine reported in Clinical Cancer Research that Rosetta's miRview squamous test classified 102 resected NSCLC samples as squamous or non-squamous with 100% concordance to classification with microscopy and...
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) MicroRNA-205 (miRNA-205) Studies in human tissue samples suggest that miRNA-205 could be a biomarker of...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

miRview squamous diagnostic data

Data from 262 patients showed that Rosetta's miRview squamous test identified squamous lung carcinomas with 96% sensitivity and 90% specificity. Data were published in the Journal of Clinical Oncology. Rosetta launched the test last December....
07:00 , Apr 17, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer microRNA-200 family; microRNA-205 family; zinc finger E-box binding homeobox 1 (ZEB1); Smad-interacting protein-1 (SIP1) In vitro studies suggest that increasing...